JOINN Laboratories

♦Service Introduction & Overview

Genetic toxicology testing is a core component of nonclinical safety assessment, designed to detect potential damage to genetic material (DNA, chromosomes) induced by test articles via standardized in vitro and in vivo assays. It predicts risks of mutagenicity, teratogenicity and carcinogenicity, representing a mandatory requirement for IND/NDA submissions of pharmaceuticals, biologics, vaccines and innovative products. JOINN Laboratories operates a state-of-the-art GLP-compliant genetic toxicology platform, conducting studies in strict alignment with ICH S2, FDA and EMA guidelines, with a full-service portfolio covering all test article types and assay categories.

We deliver distinctive genetic toxicology expertise supported by a specialized scientific team, validated models and rigorous quality control. Beyond standard genotoxicity test batteries, we lead in cutting-edge areas including reproductive and developmental genetic toxicology, large molecule biologic assessment and non-human primate (NHP) specialized testing. We established the first Cynomolgus monkey embryo-fetal developmental toxicity model in China, and our vaccine reproductive genetic toxicology protocols have repeatedly gained domestic and FDA clearance. With extensive real-world experience and strict compliance, we provide accurate, regulatory-compliant end-to-end genetic toxicology solutions for global clients.

♦Core Genetic Toxicology Assays

Bacterial Reverse Mutation Test (Ames Test)

The Ames test is a foundational genotoxicity screening assay that detects the ability of test articles to induce reverse mutations in histidine-auxotrophic Salmonella typhimurium strains, providing rapid prediction of mutagenic potential. It is the recommended first-tier assay per ICH, FDA and EMA guidelines, suitable for initial screening of small molecules, extracts and active pharmaceutical ingredients (APIs).

Services: Testing with TA97a, TA98, TA100, TA102, TA1535 standard strains; multiple dose groups, positive/negative controls; metabolic activation and non-activation arms; GLP-compliant colony counting and result interpretation.

Key Advantages: Strict strain quality control, high reproducibility; proven expertise with highly toxic test articles (e.g., antibiotics); globally acceptable, precise result interpretation.

In Vitro Chromosome Aberration Assay

This assay evaluates structural and numerical chromosomal damage induced by test articles in cultured mammalian cells, identifying clastogenic or aneugenic effects. As a core component of standard genotoxicity batteries, it is applicable to chemical drugs, biologics and medical device extracts.

Services: Testing with CHL (Chinese Hamster Lung) cell line; concentration gradients, positive/negative controls; short/long-term exposure; microscopic analysis of aberration types and frequencies; GLP-compliant reporting.

Key Advantages: Robust, quality-controlled cell culture system; specialized cytogenetic team for accurate scoring; customizable design for poorly soluble or highly toxic test articles.

In Vitro and In Vivo Micronucleus Assays

Micronucleus assays are gold-standard tests for detecting chromosomal damage or spindle dysfunction, available in in vitro cell-based and in vivo animal models. In vivo assays reflect clinical exposure scenarios and confirm in vitro findings, serving as a required in vivo component of standard genotoxicity batteries.

Services: In vitro micronucleus testing in CHL cells; in vivo micronucleus testing in SD/Wistar rats and ICR/KM/C57BL/6 mice; bone marrow/peripheral blood micronucleus analysis; GLP-aligned study conduct and data analysis.

Key Advantages: Full species coverage, flexible study design; high-sensitivity detection, reliable results; combinable with other toxicity studies to reduce timelines and costs.

Reproductive and Developmental Genetic Toxicology

Specialized assessment of reproductive, embryonic and fetal genetic toxicity across Seg.I, Seg.II and Seg.III study phases, evaluating impacts on fertility, embryonic development and offspring genetic integrity. This is a critical safety endpoint for innovative drugs, vaccines and biologics.

Services: Rodent/rabbit/Cynomolgus monkey reproductive genetic toxicology studies; in vitro whole embryo culture screening; surrogate molecule and transgenic animal assessment for biologics.

Key Advantages: First-in-China GLP Cynomolgus monkey ePPND model; FDA-cleared vaccine reproductive toxicity protocols; expert rabbit artificial insemination capability; mature in vitro whole embryo culture screening.

♦Study Models & Resources

Animal Species

• Rodents: Rats (SD, Wistar); Mice (ICR, KM, C57BL/6, Transgenic)

• Non-Rodents: Rabbits (New Zealand White, Japanese White); Non-human Primates (Cynomolgus Monkeys)

Standard Strains & Cell Lines

• Bacterial Strains: TA97a, TA98, TA100, TA102, TA1535

• Cell Line: CHL (Chinese Hamster Lung Cells)

♦Core Technical Strengths

• Extensive experience in standard reproductive and developmental genetic toxicology (Seg.I, II, III) for small molecules, biologics, siRNA and gene therapy products

• Vaccine reproductive/developmental genetic toxicology protocols repeatedly cleared by domestic regulators and FDA

• First-in-China Cynomolgus monkey embryo-fetal developmental toxicity model, with multiple GLP registration studies completed

• Industry-leading expertise in surrogate molecules and transgenic animals for biologic genotoxicity assessment

• Proven Segment II rabbit reproductive toxicity experience with specialized artificial insemination techniques

• Mature in vitro whole embryo culture for early reproductive genetic toxicity screening

• Standard GLP laboratory, professional technical team, full-process quality control, fully traceable data

♦Case Studies

Case 1: Standard Genotoxicity Battery for First-in-Class Small Molecule

Full genotoxicity package (Ames, in vitro chromosome aberration, in vivo micronucleus) for a novel oncology drug, with optimized dose design for high toxicity. GLP-compliant data supported seamless FDA IND clearance with no genotoxicity-related deficiencies.

Case 2: Reproductive Genetic Toxicology for Vaccine

Custom reproductive developmental genetic toxicology study for a novel vaccine using rodent models, designed to FDA standards. Simultaneous clearance from domestic regulators and FDA was achieved, supporting late-stage registration.

Case 3: Cynomolgus Monkey ePPND Study for Biologic

GLP-compliant Cynomolgus monkey embryo-fetal developmental toxicity study for a large molecule biologic using our in-house NHP model. As one of few CROs capable of this assay, we enabled clinical advancement for the client’s innovative biologic.

Case 4: Ames Test for Highly Toxic Antibiotic

Optimized Ames assay for a bacteriotoxic antibiotic, with refined dose and exposure conditions to distinguish cytotoxicity from mutagenicity. Regulatory-compliant results provided critical safety data for drug development.

Frequently Asked Questions (FAQ)

Q1: How many standard genotoxicity test batteries are available, and what are they?

A: Two equally acceptable standard test batteries exist. Battery 1: ① Bacterial reverse mutation (Ames) assay; ② In vitro chromosome aberration/in vitro micronucleus/mouse lymphoma TK assay; ③ In vivo genotoxicity assay (rodent hematopoietic micronucleus or chromosome aberration). Battery 2: ① Bacterial reverse mutation (Ames) assay; ② Two in vivo assays using different tissues (typically rodent hematopoietic micronucleus + liver DNA strand break assay).

Q2: How is the Ames test performed if the test article is highly toxic to bacteria?

A: The Ames test must still be conducted even for bacteriotoxic test articles (e.g., certain antibiotics), as mutagenicity often occurs at lower, less toxic concentrations. An additional in vitro mammalian cell genotoxicity assay is required, using Standard Battery 1 for full assessment.

Q3: When are follow-up genotoxicity tests needed?

A: Follow-up testing is required if standard battery results are negative, but carcinogenicity studies show increased tumor incidence without a confirmed non-genotoxic mechanism. Additional assays may include modified metabolic activation, target organ DNA damage testing (comet assay, DNA adducts), transgenic mutation analysis or molecular characterization.

Q4: How does genotoxicity assessment differ for biologics vs. small molecules?

A: Biologic assessment focuses on clinical relevance; bacterial mutation assays are often less applicable. We prioritize in vitro mammalian cell and in vivo models, using surrogate molecules and transgenic animals where appropriate, with extensive regulatory experience in this specialized area.

Q5: Are genetic toxicology reports acceptable for global regulatory submissions?

A: Yes. All studies are GLP-compliant and align with ICH S2, FDA, EMA and NMPA requirements. Reports include fully traceable, audit-ready data for IND, NDA and global registration submissions.

Q6: Do you offer non-human primate genetic toxicology studies?

A: Yes. We developed and conduct the first GLP Cynomolgus monkey embryo-fetal developmental toxicity (ePPND) studies in China, supporting advanced assessment for highly innovative and specialized biologics.

Genetic Toxicology Studies